Linacip 5mg Tablet contains Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Linagliptin works by enhancing the incretin system, which increases insulin secretion and decreases glucagon release in a glucose-dependent manner, thereby improving glycemic control. This agent is typically prescribed as an adjunct to diet and exercise to improve glycemic parameters in adults inadequately controlled by lifestyle modifications alone or in combination with other antidiabetic medications. Linacip 5mg is administered orally once daily, with or without food, and does not require dose adjustment in patients with renal impairment, making it suitable for a broad patient population. Clinical studies have demonstrated that Linagliptin effectively reduces HbA1c levels with a low risk of hypoglycemia when used as monotherapy or in combination therapy. Common adverse effects may include nasopharyngitis, headache, and upper respiratory tract infections, though it is generally well tolerated. Caution is advised in patients with a history of pancreatitis. Regular monitoring of blood glucose and renal function is recommended during therapy to optimize treatment outcomes and ensure patient safety.

Dosage & How to Use